Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
5(83.3%)
Early Phase 1
1(16.7%)
6Total
Phase 2(5)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07150845Phase 2Recruiting

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Role: lead

NCT06873516Phase 2Active Not Recruiting

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

Role: lead

NCT06723405Phase 2Completed

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

Role: lead

NCT06603220Phase 2Completed

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Role: lead

NCT05579899Phase 2Completed

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

Role: lead

NCT06645821Early Phase 1Recruiting

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

Role: collaborator

All 6 trials loaded